Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $250

SVB Leerink analyst Puneet Souda maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $220 to $250.

byBenzinga Newsdesk

August 3, 2022

1 minute read

SVB Leerink analyst Puneet Souda maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $220 to $250.

Deutsche Bank Maintains Buy on Meta Platforms, Lowers Price Target to $125

By Benzinga Newsdesk

Today, 5:54 AM

Deutsche Bank analyst Benjamin Black maintains Meta Platforms (NASDAQ:META) with a Buy and lowers the price target from $170 to $125.

FDA Says Concluded These Batches Manufactured At Emergent Facility Are Suitable For Use; Says Conducted Thorough Review Of Facility, Results Of Quality Testing Performed By Manufacturer

By Michael Horton

Today, 5:54 AM

-Reuters

EBS

Analyst Ratings

Expert Ratings For MercadoLibre

By Benzinga Insights

Today, 5:54 AM

Analysts have provided the following ratings for MercadoLibre (NASDAQ:MELI) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

MELI

Acuity Brands Q4 Earnings Beat Estimates

By Akanksha

Today, 5:54 AM

Acuity Brands, Inc. (NYSE:AYI) reported fourth-quarter FY21 sales growth of 11.4% year-over-year to $992.7 million, beating the consensus of $963.96 million.…

AYI

SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $250

Related Posts

Deutsche Bank Maintains Buy on Meta Platforms, Lowers Price Target to $125

FDA Says Concluded These Batches Manufactured At Emergent Facility Are Suitable For Use; Says Conducted Thorough Review Of Facility, Results Of Quality Testing Performed By Manufacturer

Expert Ratings For MercadoLibre

Acuity Brands Q4 Earnings Beat Estimates